AliveCor, a Mountain View, CA-based provider of FDA-cleared personal electrocardiogram (ECG) technology solutions, raised an undisclosed amount in Series F funding.
The round was led by GE Healthcare, with participation from NGK-NTK (through a CVC partnership with Pegasus Tech Ventures) and existing investors including Khosla Ventures, Bold Capital Partners, Qualcomm Ventures, and WP Global Partners.
The company intends to use the funds to expand its development efforts.
Led by CEO Priya Abani, AliveCor provides:
- the FDA-cleared KardiaMobile device, a clinically validated personal ECG solution
- KardiaMobile 6L, which provides instant detection of Atrial Fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with Supraventricular Ectopy, Sinus Rhythm with Premature Ventricular Contractions, Sinus Rhythm with Wide QRS, and Normal Sinus Rhythm in an ECG
- Kardia, an AI-enabled platform to aid patients and clinicians in the efficient detection of atrial fibrillation, the most common arrhythmia and one associated with a highly elevated risk of stroke
- An enterprise platform, including KardiaComplete for payors, employers, and health systems, which allows third-party providers to manage their patients’ and customers’ heart conditions simply using tools that provide front-end and back-end integration to AliveCor technologies
- A digital health subscription service, KardiaCare, which offers more than 130,000 members a suite of advanced features to understand and manage their heart health.
FinSMEs
17/08/2022